



ESSEX BIO-TECHNOLOGY LIMITED
億勝生物科技有限公司

Press Release

STRATEGIC ACQUISITION OF 51% STAKE IN YANTAI BAOYUAN

AN EXPANSION INTO ANOTHER BIO-TECHNOLOGY RELATED INDUSTRY

Hong Kong, 8 November 2005 - - ESSEX BIO-TECHNOLOGY LIMITED (“Essex” or the “Group” - Stock Code: 8151) today announced that the Company, through its wholly-owned subsidiary, Essex Bio-Investment Limited (“Essex Bio-Investment”) entered into the Capital Injection Agreement on 4 November 2005 to which Essex Bio-Investment will pay the consideration of HK\$5,388,500 (equivalent to approximately RMB5,620,000), at par value per share, in cash as contribution to the registered capital of Baoyuan Bio-Agri Technology (Yantai) Ltd. (“Yantai Baoyuan”).

Upon completion of the Capital Injection, Essex Bio-Investment will be having 51% of the equity interest in Yantai Baoyuan.

Yantai Baoyuan was incorporated and based in Shandong, the PRC and it is principally engaged in the research, development and production of organic and chemical formulated agricultural fertilizers, in solid and liquid forms, for the agriculture industry in the PRC.

Essex Bio-Investment has also agreed to provide an interest-free shareholders’ loan in an aggregate principal amount of HK\$4,200,000 (equivalent to approximately RMB4,381,000) as working capital to Yantai Baoyuan after completion of the Capital Injection.

Essex Chairman Patrick NGIAM said: “The investment in Yantai Baoyuan is part of the Group’s expansion plan into another bio-technology related industry, on the basis that it shall contribute to the positive growth and enhance the Shareholders’ value of the Group”.

About Essex Bio-Technology Limited:

Essex Bio-Technology Limited (“Essex”) was listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited on 27 June 2001. Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It was principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds and the research and development of biopharmaceutical products for the treatment of duodenal ulcers and nervous system damages and diseases, as well as other ophthalmic pharmaceutical projects.

The Group currently has two commercialised biopharmaceutical products, namely Beifuji in liquid form, lyophilised powder form and gel form and Beifushu in eye-drop form for the treatment and healing of acute and chronic surface wounds and corneal wounds respectively.

- End -

For more information, please contact:

Essex Bio-Technology Limited

Email : essex@essexbio.com

Tel : (852) 2587-7838